Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 29, 1997

View Archived Issues

Allergan Ligand Retinoid Therapeutics disbanded; products reallocated to Ligand and Allergan

Glaxo Wellcome describes new agents for CMV

New morphinoid delta-opioid ligands from SmithKline Beecham

SKB reports new antiplatelet agents

Tachykinin antagonists prepared at Pfizer

Apligraf burn study results presented at scientific symposium

Rhone-Poulenc Rorer discloses excitatory amino acid antagonists

Endothelin agonists/antagonists from Texas Biotechnology

Phosphomannose isomerase as target for antifungal drugs

Zeneca describes SAR for new asthma therapy in development

SB-244875: a new bone resorption inhibitor

Sumitomo prepares bone-selective bisphosphonate-estrogen conjugates

Cancer gene therapy shows long-term benefits in mice

Design and synthesis of COX-2 inhibitors related to indomethacin

Celgene seeks FDA approval for clinical trials with thalidomide for autoimmune disorders

Taxotere efficacy demonstrated in NSCLC, gastric cancer

Synaptic focuses on dihydropyrimidinones for BPH

ICOS commences phase II trial for ischemic stroke; analyzes data for other indications

Mechanism of action revealed for Theratechnologies' Protectazem

Phase II trial begins for Neurobiological Technologies' antiedema agent

Betathine available for licensing from Dovetail

Ribi's melanoma vaccine accepted for fast-track review in Canada

Allergan and Acadia enter drug discovery collaboration

New oxazolidinone from P&U described at ICAAC

Bosentan evaluated in humans for preventing ciclosporin nephrotoxicity

Improved oxazolidinone prodrugs reported at ICAAC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...